Frontiers in Cellular and Infection Microbiology (Aug 2022)

Metagenomic next-generation sequencing for identifying pathogens in patients with rheumatic diseases and diffuse pulmonary lesions: A retrospective diagnostic study

  • Juan Jiang,
  • Juan Jiang,
  • Juan Jiang,
  • Juan Jiang,
  • Juan Jiang,
  • Wei Yang,
  • Wei Yang,
  • Wei Yang,
  • Wei Yang,
  • Wei Yang,
  • Yanhao Wu,
  • Yanhao Wu,
  • Yanhao Wu,
  • Yanhao Wu,
  • Yanhao Wu,
  • Wenzhong Peng,
  • Wenzhong Peng,
  • Wenzhong Peng,
  • Wenzhong Peng,
  • Wenzhong Peng,
  • Wenjuan Zhang,
  • Wenjuan Zhang,
  • Wenjuan Zhang,
  • Wenjuan Zhang,
  • Wenjuan Zhang,
  • Pinhua Pan,
  • Pinhua Pan,
  • Pinhua Pan,
  • Pinhua Pan,
  • Pinhua Pan,
  • Chengping Hu,
  • Chengping Hu,
  • Chengping Hu,
  • Chengping Hu,
  • Chengping Hu,
  • Yisha Li,
  • Yisha Li,
  • Yuanyuan Li,
  • Yuanyuan Li,
  • Yuanyuan Li,
  • Yuanyuan Li,
  • Yuanyuan Li

DOI
https://doi.org/10.3389/fcimb.2022.963611
Journal volume & issue
Vol. 12

Abstract

Read online

ObjectiveLung involvement is a major cause of morbidity and mortality in patients with rheumatic diseases. This study aimed to assess the application value of metagenomic next-generation sequencing (mNGS) for identifying pathogens in patients with rheumatic diseases and diffuse pulmonary lesions.MethodsThis retrospective study included patients who were diagnosed with rheumatic diseases and presenting diffuse pulmonary lesions on chest radiography in Xiangya Hospital from July 2018 to May 2022. Clinical characteristics were summarized, including demographics, symptoms, comorbidities, radiological and laboratory findings, and clinical outcomes. Pulmonary infection features of these patients were analyzed. Furthermore, diagnostic performance of mNGS and conventional methods (including smear microscopy, culture, polymerase chain reaction assay, and serum immunological test) in identifying pulmonary infections and causative pathogens were compared.ResultsA total of 98 patients were included, with a median age of 58.0 years old and a female proportion of 59.2%. Of these patients, 71.4% showed the evidence of pulmonary infections. Combining the results of mNGS and conventional methods, 129 infection events were detected, including 45 bacterial, 40 fungal and 44 viral infection events. Pulmonary mixed infections were observed in 38.8% of patients. The detection rates of mNGS for any pathogen (71.4% vs 40.8%, P < 0.001) and mixed pathogens (40.8% vs 12.2%, P < 0.001) were higher than that of conventional methods. Moreover, mNGS had a significantly higher sensitivity (97.1% vs. 57.1%, P < 0.001) than conventional methods in identifying pulmonary infections, while its specificity (92.9% vs. 96.4%, P = 0.553) were comparable to conventional methods. Antimicrobial and antirheumatic treatments were markedly modified based on mNGS results in patients with rheumatic diseases and diffuse pulmonary lesions.ConclusionsFor patients diagnosed with rheumatic diseases and presenting diffuse pulmonary lesions, mNGS is a powerful complement to conventional methods in pathogen identification due to its high efficiency and broad spectrum. Early application of mNGS can provide guidance for precision treatment, and may reduce mortality and avoid antibiotic abuse.

Keywords